Clinique Ovo
Montreal, Quebec, H4P 2S4, Canada
NCT Number: NCT05866484
Normal embryonic development relies on the correct transmission of genetic information, and sperm DNA plays a crucial part in this process. Causes of poor sperm DNA integrity include unhealthy lifestyles such as smoking and exposure to gonadotoxins, as well as, obesity, varicoceles, infections, advanced paternal age and systemic disorders. An increase in DNA fragmentation in sperm has been linked to lower fertilisation rate, poorer quality embryos, lower pregnancy rate, and high miscarriages rate.
The best way for sperm selection and processing in assisted reproductive technologies (ART) should be noninvasive and cost-effective. It should also make it possible to identify high-quality spermatozoa and produce more favorable results in terms of pregnancy and live birth rates.7 Meanwhile, the microfluidic sperm separation technology is a less expensive and less invasive alternative. This method allows for the selection of motile sperm that have a normal morphology, low levels of reactive oxygen species (ROS), and low DFI
Looking for future studies?
Notify Me18 year and older
Male
Observational
Montreal, Quebec, H4P 2S4, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: approximately 8 weeks
Compare clinical pregnancy rate in couples with high Sperm DNA fragmentation
Time frame: Approximately 20 days
Compare the number of utilizable embryos obtained in couples using TESA-ICSI vs Zymot-ICSI
Clinique Ovo
Industry
Testicular Sperm Aspiration (TESA) vs. Microfluidic Sperm Separation (MSS) in Couples With High Sperm DNA Fragmentation Undergoing ICSI: Which Approach is Better
Acronym: TESA vs Zymot
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05628987
Asthenozoospermia, Azoospermia
Guangzhou, Guangdong, China
View Trial DetailsNCT02932865
Azoospermia, Genital Diseases
Turku, Finland
View Trial DetailsNCT05399212
Endocrine System Diseases, Genital Diseases
Hồ Chí Minh, Ho Chi Minh City, Vietnam
View Trial DetailsNCT03712982
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Waltham, Massachusetts, United States
View Trial Details